Abstract library

1909 results for "endocrine pancreatic carcinoma".
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#74 Non-functioning pancreatic endocrine tumors: diagnostic criteria and surgical treatment
Introduction: Neuroendocrine tumors were considered rare tumors several years ago. Several reports published recently have observed increased incidence of NETs suggesting that NETs are more prevalent than previously reported. Non-functioning pancreatic endocrine tumors (NFPETs), better defined as non-hyperfunctioning, are characterized by the absence of clinical or biochemical evidence of hormone hypersecretion. From the clinical standpoint, NFPETs can be either occasionally encountered or manifest clinically similar pancreatic tumors. Since both NFPET treatment and prognosis significantly differ from that of ductal adenocarcinoma and other pancreatic malignant tumors, an accurate differential diagnosis is needed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alexander Vladimir Kochatkov
#76 Role of contrast-enhanced ultrasonography in the differential diagnosis of the pancreatic and hepatic lesions
Introduction: Contrast-enhanced ultrasonography (CEUS) is a new promising tool for the characterization of pancreatic lesions. This technique allows for highlighting the micro-vascularization of a lesion, especially with the use of second generation contrast media, characterized by harmonic responses at low acoustic pressures. Pancreatic endocrine tumors (PET)s were reported to have a peculiar behavior at CEUS, consisting of a higher enhancement compared to normal pancreas in the arterial phase and a rapid washout.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Francesco Milone
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#1150 Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals.
Introduction: Platelets carry VEGF-A, serotonin and dopamine. Serotonin stimulates and dopamine inhibits tumor angiogenesis. We hypothesized that platelets are activated in tumor vasculature and release angiogenic factors, resulting in lower platelet serotonin and dopamine.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Marloes Peters
#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#719 Mixed Exocrine-Endocrine Pancreatic Tumors
Introduction: Mixed pancreatic tumors are very rare, characterized by association of exocrine (ductal or acinar) and endocrine components, and positivity for neuroendocrine (NE) markers in >30% of cells.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: professor Claudio Pasquali